% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Beschorner:281845,
author = {Beschorner, Natalie and Xu, Ying and Jucker, Mathias and
Ruiz-Riquelme, Alejandro},
title = {{A}myloid‐β {S}eeds in {A}lzheimer's {D}isease:
{R}esearch {C}hallenges and {I}mplications},
journal = {Journal of neurochemistry},
volume = {169},
number = {11},
issn = {0022-3042},
address = {Oxford},
publisher = {Wiley-Blackwell},
reportid = {DZNE-2025-01224},
pages = {e70267},
year = {2025},
abstract = {The amyloid cascade hypothesis, proposed over 30 years ago,
places amyloid-β (Aβ) at the center of Alzheimer's disease
(AD) pathogenesis. Though controversial, recent clinical
successes with Aβ-targeting therapies have reinforced its
importance. However, these treatments have shown only modest
clinical benefits in line with a two-stage AD progression:
an early phase driven by Aβ-seed and a later phase that
progresses at least partly independently of Aβ. Evidence of
Aβ seed transmission in humans raises both therapeutic
potential and biosafety concerns. This review explores
current understanding of Aβ seeds, including challenges in
studying such seeds, model systems to study Aβ seeds, and
biosafety issues when working with Aβ seeds.},
subtyp = {Review Article},
keywords = {Alzheimer Disease: metabolism / Alzheimer Disease:
pathology / Humans / Amyloid beta-Peptides: metabolism /
Animals},
cin = {AG Petzold / AG Jucker},
ddc = {610},
cid = {I:(DE-2719)1013020 / I:(DE-2719)1210001},
pnm = {353 - Clinical and Health Care Research (POF4-353) / 352 -
Disease Mechanisms (POF4-352)},
pid = {G:(DE-HGF)POF4-353 / G:(DE-HGF)POF4-352},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:41185432},
pmc = {pmc:PMC12583922},
doi = {10.1111/jnc.70267},
url = {https://pub.dzne.de/record/281845},
}